Key rules
- Measurable lesion: at least 10 mm (lymph node: short axis 15 mm or more) [1].
- At most 5 target lesions and 2 per organ [1].
- CR: disappearance of all lesions and nodes below 10 mm; PR: a decrease of 30% or more from baseline; PD: an increase of 20% or more over the smallest sum and at least 5 mm, or a new lesion; SD: everything else [1].
- iRECIST: with immunotherapy, the first progression is “unconfirmed” (iUPD) and becomes “confirmed” (iCPD) if it increases further 4–8 weeks later [2].
Full lesson: assessing tumour response.
References
2 referencesShow all referencesClose the reference list
Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.
- 1
- 2iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
This page is based on reputable scientific sources and was last updated on 27 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.
Printed from the website; the full and up-to-date version: https://drdabiri.com/en/tools/recist-response-calculator/